"10.1371_journal.pone.0122722","plos one","2015-04-16T00:00:00Z","Maibritt B Andersen; Carrie Hughes Croy; Ditte Dencker; Thomas Werge; Frank P Bymaster; Christian C Felder; Anders Fink-Jensen","Research Institute of Biological Psychiatry, Sct. Hans Hospital, Roskilde, Denmark; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America; Laboratory of Neuropsychiatry, Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark; Psychiatric Centre Copenhagen, University of Copenhagen, Copenhagen, Denmark; Euthymics Bioscience Inc, 43 Thorndike St Suite 1-3, Cambridge, Massachusetts, United States of America","Conceived and designed the experiments: AFJ MA TW CHC CF. Performed the experiments: CHC MA. Analyzed the data: CHC CF MA AFJ DD. Contributed reagents/materials/analysis tools: CHC CF MA AFJ. Wrote the paper: MA CHC DD TW FB CF AFJ.","CHC and CF were full-time employees of Eli Lilly at the time the experiments were performed and the GTP-Î³-[35S] binding experiments included in this manuscript have been financially supported by Eli Lilly. FB was employed at Euthymics Bioscience Inc. The muscarinic compounds BuTAC, PTAC and xanomeline used in the study, were synthesized at Eli Lilly. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2015","04","Maibritt B Andersen","MBA",7,TRUE,5,2,5,7,TRUE,TRUE,FALSE,0,NA,FALSE
